These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 11704799)

  • 1. Hematologic and cytogenetic remission by STI571 (Glivec) in a patient relapsing with accelerated phase CML after second allogeneic stem cell transplantation.
    Wassmann B; Klein SA; Scheuring U; Pfeifer H; Martin H; Gschaidmeier H; Hoelzer D; Ottmann OG
    Bone Marrow Transplant; 2001 Oct; 28(7):721-4. PubMed ID: 11704799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
    DeAngelo DJ; Hochberg EP; Alyea EP; Longtine J; Lee S; Galinsky I; Parekkedon B; Ritz J; Antin JH; Stone RM; Soiffer RJ
    Clin Cancer Res; 2004 Aug; 10(15):5065-71. PubMed ID: 15297408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
    Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
    Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. STI571 (GLIVEC) induced hematologic, cytogenetic and molecular remission in a cml patient relapsing with accelerated phase after allogeneic stem cell transplantation.
    Consoli U; Milone G; Guido G; Consoli C; Palumbo GA; Giustolisi R
    Haematologica; 2002 Dec; 87(12):ECR37. PubMed ID: 12495908
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of induced GVHD in leukemia patients relapsing after allogeneic bone marrow transplantation: single-center experience of 33 adult patients.
    Min CK; Eom KS; Lee S; Kim DW; Lee JW; Min WS; Kim CC
    Bone Marrow Transplant; 2001 May; 27(9):999-1005. PubMed ID: 11436112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Imatinib mesylate (Glivec) in treatment of chronic phase chronic myeloid leukemia].
    Voglová J; Poznarová A; Chrobák L; Rabasová J; Beránek M; Moravcová J; Faber E; Klamová H; Cikhart M
    Vnitr Lek; 2004 Jan; 50(1):21-3, 26-9. PubMed ID: 15015226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Results up to now of administration of STI-571 (Glivec) in recurrence after allogenic and autologous stem cell transplantation in chronic myeloid leukemia].
    Fischer T
    Med Klin (Munich); 2002 Jan; 97 Suppl 1():22-7. PubMed ID: 11831068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Favorable outcome with STI571 (imatinib mesylate) and allogeneic stem cell transplantation in a case of Ph+ chemorefractory acute lymphocytic leukaemia.
    Wernstedt P; Brune M; Andersson PO; Gustavsson B; Stockelberg D; Wadenvik H
    Bone Marrow Transplant; 2002 Dec; 30(12):971-3. PubMed ID: 12476293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic strategies for chronic myeloid leukemia in the chronic (stable) phase.
    Goldman JM
    Semin Hematol; 2003 Jan; 40(1 Suppl 1):10-7. PubMed ID: 12682876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation.
    Weisser M; Tischer J; Schnittger S; Schoch C; Ledderose G; Kolb HJ
    Haematologica; 2006 May; 91(5):663-6. PubMed ID: 16627251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autologous reconstitution combined with durable leukemic remission after allogeneic BMT for CML: absence of persistence of a donor-derived T cell effector population.
    Maury S; Belhadj K; Chami I; Kuentz M; Cordonnier C; Bories D
    Bone Marrow Transplant; 2001 Oct; 28(7):717-20. PubMed ID: 11704798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stable molecular remission induced by imatinib mesylate (STI571) in a patient with CML lymphoid blast crisis relapsing after allogeneic stem cell transplantation.
    Wassmann B; Scheuring U; Thiede C; Pfeifer H; Bornhäuser M; Griesinger F; Hochhaus A; Schleyer E; Gschaidmeier H; Hoelzer D; Ottmann OG
    Bone Marrow Transplant; 2003 Apr; 31(7):611-4. PubMed ID: 12692630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Therapeutic efficacy of imatinib mesylate (glivec) in chronic phase of myeloid leukemia].
    Turkina AG; Khoroshko ND; Druzhkova GA; Zingerman BV; Zakharova ES; Chelysheva EIu; Vinogradova OIu; Domracheva EV; Zakharova AV; Kovaleva LG
    Ter Arkh; 2003; 75(8):62-7. PubMed ID: 14520855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Second transplant from the same donor without conditioning for bone marrow aplasia after non-myeloablative hematopoietic stem cell transplantation for chronic myeloid leukemia].
    Ishikawa I; Miyamura K; Yamada M; Sasaki O; Harigae H; Kameoka J; Meguro K; Sasaki T
    Rinsho Ketsueki; 2005 Dec; 46(12):1288-92. PubMed ID: 16447801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A retrospective single centre study of the outcome of five different therapy approaches in 48 patients with relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation.
    Elmaagacli AH; Beelen DW; Schaefer UW
    Bone Marrow Transplant; 1997 Dec; 20(12):1045-55. PubMed ID: 9466277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reducing transplant-related mortality after allogeneic hematopoietic stem cell transplantation.
    Bacigalupo A; Sormani MP; Lamparelli T; Gualandi F; Occhini D; Bregante S; Raiola AM; di Grazia C; Dominietto A; Tedone E; Piaggio G; Podesta M; Bruno B; Oneto R; Lombardi A; Frassoni F; Rolla D; Rollandi G; Viscoli C; Ferro C; Garbarino L; Van Lint MT
    Haematologica; 2004 Oct; 89(10):1238-47. PubMed ID: 15477210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolonged remission of accelerated phase Philadelphia chromosome negative chronic myeloid leukemia following autologous recovery of normal hematopoietic elements after busulfan/cyclophosphamide and allogeneic marrow transplantation.
    Kapoor N; Keever CA; Hsu SH; Copelan EA; Tutschka PJ
    Bone Marrow Transplant; 1992 Feb; 9(2):143-5. PubMed ID: 1349249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tyrosine kinase inhibitor STI571 in the treatment of Philadelphia chromosome-positive leukaemia failing myeloablative stem cell transplantation.
    Au WY; Lie AK; Ma SK; Wan TS; Liang R; Chan EC; Kwong YL
    Bone Marrow Transplant; 2002 Oct; 30(7):453-7. PubMed ID: 12368958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activated allogeneic cell therapy (allo-ACT) for relapsed chronic myelogenous leukemia (CML) refractory to buffy coat transfusions post-allogeneic bone marrow transplantation.
    Kapelushnik J; Nagler A; Or R; Naparstek E; Ackerstein A; Samuel S; Morecki S; Nabet C; Slavin S
    Bone Marrow Transplant; 1996 Dec; 18(6):1153-6. PubMed ID: 8971387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.